Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.4% during the third quarter, Holdings Channel.com reports. The firm owned 59,164 shares of the biopharmaceutical company’s stock after purchasing an additional 1,967 shares during the quarter. Franklin Resources Inc.’s holdings in Catalyst Pharmaceuticals were worth $1,221,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $50,000. Larson Financial Group LLC grew its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Meeder Asset Management Inc. purchased a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $70,000. Finally, Quantbot Technologies LP acquired a new position in Catalyst Pharmaceuticals during the third quarter worth $151,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on CPRX. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $21.47 on Friday. The firm has a market capitalization of $2.56 billion, a PE ratio of 18.19, a P/E/G ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.12 and a 12 month high of $24.27. The business has a 50-day moving average of $21.82 and a two-hundred day moving average of $19.49.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.